"10.1371_journal.pone.0065317","plos one","2013-06-06T00:00:00Z","Roxanne Dutia; Andrea J Kim; Matthew Modes; Robert Rothlein; Jane M Shen; Ye Edward Tian; Jumana Ihbais; Sam F Victory; Carmen Valcarce; Sharon L Wardlaw","Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York, United States of America; TransTech Pharma, Inc., High Point, North Carolina, United States of America","Conceived and designed the experiments: RD SLW. Performed the experiments: RD AJK MM. Analyzed the data: RD SLW. Contributed reagents/materials/analysis tools: RR JMS YET JI SFV CV. Wrote the paper: RD SLW. Involved with development, production and characterization of TTP2515: RR JMS YET JI SFV CV. Participated on behalf of TransTech Pharma in the initial experimental design of these studies: RR JMS YET. Performed studies with TTP2515 in HEK293 cells: YET.","JMS, YET, JI, SFV and CV are employed by TransTech Pharma, Inc. TransTech Pharma Inc. has developed a small molecule, non-peptide, orally active AgRP inhibitor, TTP 2515, which was used in this study. TTP2515 and its uses are covered by a pending United States Patent Application that is owned by TransTech Pharma. The United States Patent Application Number is 12/547,018, and the application was published as United States Patent Publication Number 2010-0056587. There are no further patents, products in development or marketed products to declare. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","06","Roxanne Dutia","RD",10,TRUE,2,3,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
